AstraZeneca LP v. Breath Limited, No. 15-1335 (Fed. Cir. May 7, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This Hatch-Waxman case returns to us following our previous remand to the district court. The suit originates from a consolidated action for patent infringement brought by AstraZeneca LP and AstraZeneca AB (colle c- tively, “AstraZeneca”) against Breath Limited, Apotex Corp., Apotex, Inc., Sandoz Inc., and Watson Laborat o- ries, Inc. (collectively, “Defendants”). In our prior decision and of relevance here, we reversed and remanded the district court’s noninfringement findings on AstraZeneca’s U.S. Patent No.